Age (LR Group: 64 vs. RR Group: 68, p = 0.438), BMI (LR Group: 25.45 kg/m2 vs. RR Group: 25.1 kg/m2, p = 0.654), ASA stage (p = 0.122), tumor location, preoperative CEA level (LR Group: 2.4 μg/L vs. RR Group: 2.1 μg/L, p = 0.468), comorbidities (p = 0.328), previous surgery rate (LR Group: 18 (21.95%) vs. RR Group: 32 (34.41%), p = 0.056, preoperative clinical stage (p = 0.611) and type of preoperative therapy in the case of rectal cancer (p = 0.344) did not differ between groups. The gene discussed is CEACAM5; the disease is rectal cancer.